Venus Remedies Limited (IN:VENUSREM)
:VENUSREM
Top Page
Venus Remedies Limited
(VENUSREM)
Select Model
Select Model
Rating:79Outperform
Price Target:
₹1,138.00
▲(45.48% Upside)
Action:ReiteratedDate:03/13/26
The score is driven primarily by strong financial performance (improving profitability, low leverage, and robust free cash flow). Technicals also support the rating with a clear uptrend and positive momentum, while valuation is supportive due to a low P/E.
Positive Factors
Strong free cash flow
Sustained positive free cash flow indicates the business converts earnings into cash after capex, supporting reinvestment, working capital, debt reduction or shareholder returns. Durable cash generation enhances resilience and funds strategic R&D or capacity expansion over months.
Negative Factors
Moderate revenue growth rate
Single-digit revenue growth suggests limited top-line expansion versus higher-growth healthcare segments. Over a 2–6 month horizon this can constrain the company’s ability to scale R&D, absorb input-cost inflation, or achieve material market-share gains without new product launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Sustained positive free cash flow indicates the business converts earnings into cash after capex, supporting reinvestment, working capital, debt reduction or shareholder returns. Durable cash generation enhances resilience and funds strategic R&D or capacity expansion over months.
Read all positive factors
Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹13.29B
Dividend YieldN/A
Average Volume (3M)2.33K
Price to Earnings (P/E)10.0
Beta (1Y)0.60
Revenue Growth13.32%
EPS Growth218.38%
CountryIN
Employees1,187
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)19.14
Shares Outstanding13,366,988
10 Day Avg. Volume2,529
30 Day Avg. Volume2,330
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.75
Price to Sales (P/S)0.65
P/FCF Ratio5.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Venus Remedies Limited Business Overview & Revenue Model
Company Description
Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant,...
How the Company Makes Money
Venus Remedies makes money primarily by selling pharmaceutical products. Its main revenue stream is the manufacture and sale of finished formulations—especially hospital and critical-care medicines (notably anti-infectives/antibiotics)—to customer...
Venus Remedies Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
75
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.96B | 6.48B | 5.91B | 5.56B | 5.99B | 5.48B |
| Gross Profit | 2.76B | 1.66B | 2.18B | 2.25B | 2.00B | 1.07B |
| EBITDA | 1.18B | 944.10M | 711.80M | 703.46M | 701.40M | 968.49M |
| Net Income | 703.30M | 453.20M | 284.91M | 265.70M | 407.24M | 617.65M |
Balance Sheet | ||||||
| Total Assets | 7.68B | 7.16B | 6.27B | 6.01B | 5.80B | 5.56B |
| Cash, Cash Equivalents and Short-Term Investments | 2.36B | 1.64B | 838.05M | 720.77M | 432.56M | 288.79M |
| Total Debt | 143.80M | 16.90M | 413.25M | 422.90M | 428.45M | 513.18M |
| Total Liabilities | 1.74B | 1.55B | 1.39B | 1.41B | 1.39B | 1.56B |
| Stockholders Equity | 5.94B | 5.61B | 4.88B | 4.60B | 4.40B | 4.00B |
Cash Flow | ||||||
| Free Cash Flow | 682.20M | 812.90M | 278.40M | 288.02M | 272.94M | 1.25B |
| Operating Cash Flow | 811.10M | 909.20M | 372.85M | 366.20M | 410.01M | 1.33B |
| Investing Cash Flow | -1.27B | -807.90M | -72.09M | -508.30M | -166.26M | 557.16M |
| Financing Cash Flow | 126.70M | -9.50M | -10.83M | -5.70M | -94.77M | -1.62B |
Venus Remedies Limited Technical Analysis
Positive
782.25
Price Trends
803.29
Positive
769.46
Positive
618.88
Positive
Market Momentum
47.85
Negative
69.03
Neutral
87.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Positive. The current price of 782.25 is below the 20-day moving average (MA) of 897.35, below the 50-day MA of 803.29, and above the 200-day MA of 618.88, indicating a bullish trend. The MACD of 47.85 indicates Negative momentum. The RSI at 69.03 is Neutral, neither overbought nor oversold. The STOCH value of 87.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VENUSREM.
Venus Remedies Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹13.29B | 10.01 | ― | ― | 13.32% | 218.38% | |
65 Neutral | ₹11.51B | 18.86 | ― | ― | -37.70% | -19.79% | |
63 Neutral | ₹3.56B | 19.99 | ― | ― | -5.82% | -59.22% | |
56 Neutral | ₹4.49B | 34.53 | ― | ― | 32.95% | 67.39% | |
55 Neutral | ₹3.29B | 56.53 | ― | 0.26% | -9.16% | 49.09% | |
52 Neutral | ₹2.65B | 7.63 | ― | ― | -30.27% | -3470.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:VENUSREM
Venus Remedies Limited
994.15
682.60
219.10%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
141.05
54.67
63.29%
IN:KILITCH
Kilitch Drugs (India) Limited
128.35
-33.83
-20.86%
IN:MEDICAMEQ
Medicamen Biotech Limited
242.45
-250.07
-50.77%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.82
-10.96
-48.11%
IN:ZIMLAB
Zim Laboratories Ltd.
73.07
-14.93
-16.97%
Venus Remedies Limited Corporate Events
Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests
Mar 10, 2026
Venus Remedies has notified stock exchanges that it has used its official social media channels to inform shareholders about a special window for re-lodgement of transfer requests for physical shares. The communication aligns with recent Securitie...
Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers
Jan 31, 2026
Venus Remedies Limited has notified the stock exchange that it has published its unaudited financial results for the period ended 31 December 2025 in newspapers, in compliance with disclosure requirements under Regulation 30 of the Listing Obligat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.